[Nicorandil in the treatment of patients with ischemic heart disease].
Adequate drug therapy of stable ischemic heart disease directed at reduction and prevention of main clinical symptoms of the disease, increase of exercise tolerance to physical effort, improvement of quality of life and prognosis remains an actual problem. Nicorandil combines properties of an antianginal drug and cardioprotective effects. Its pharmacological action is related to capabilities to be an nitrous oxide donor and to activate ATP-dependent potassium channels. In this review we present data on mechanism of action of nicorandil, on its clinical effectiveness, and on comparison with antianginal drugs of other groups. We have also analyzed experience of the use of nicorandil in patients with acute coronary syndrome and in conjunction with during invasive interventions.